Rockwell is developing unique, proprietary renal drug therapies. These exclusive renal drugs support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe, effective therapy, while decreasing drug administration costs and improving patient convenience and outcome.
Soluble Ferric Pyrophosphate (SFP) is the Company’s lead investigational drug. SFP is a proprietary, water-soluble iron salt designed to treat or prevent iron deficiency anemia. SFP travels to the bloodstream and avoids entering the liver and reticuloendothelial system (RES), and is designed to be readily bio-available and deliver iron in a physiological manner; similar to how a healthy person receives iron from their daily dietary intake. SFP administration via dialysate has the potential to improve patient outcome as it relates to iron maintenance therapy within ESRD.
SFP has begun final Phase III efficacy studies. Upon FDA market approval, SFP is expected to provide dialysis patients iron-maintenance therapy benefits currently unavailable.
Rockwell is further developing brand extensions and new drug opportunities in the areas of anemia for women’s health, oncology, gastroenterology and parenteral nutrition, as well as new drugs for other targeted renal therapies and indications.